VolitionRx Limited (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition’s strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization.
Volition said the collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. The company believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring and address a commercial opportunity with an estimated total addressable market of $3.8 billion.
This partnership is significant because it combines Volition’s innovative Nu.Q® NETs technology with Sysmex’s global reach and established diagnostic platforms. NETosis, the process that the assay targets, is involved in a range of serious conditions, from sepsis to autoimmune diseases. By optimizing the assay on Sysmex’s systems, the collaboration aims to bring a potentially life-saving diagnostic tool to market more efficiently. For patients, this could mean earlier detection and better monitoring of diseases that currently have limited diagnostic options. For the healthcare industry, it represents a step toward more precise and accessible testing for NETosis-related conditions.
The $3.8 billion addressable market underscores the wide applicability of the Nu.Q® NETs assay. Sepsis alone affects millions worldwide and is a leading cause of death, often difficult to diagnose quickly. Improved diagnostic information could lead to earlier interventions, potentially reducing mortality rates and healthcare costs. Additionally, the assay’s potential for patient monitoring could help clinicians track disease progression and treatment response in real-time, personalizing care for acute and chronic conditions.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company’s website at https://volition.com/.
The collaboration with Sysmex marks a key milestone in Volition’s strategy to license its technology to larger partners. By working with a global diagnostics leader, Volition can tap into Sysmex’s regulatory expertise and extensive installed base of analyzers, potentially speeding up the path to market. This approach allows Volition to focus on innovation while partners handle commercialization, a model that could be replicated for other assays in its pipeline.
For the broader industry, this collaboration highlights the growing interest in NETosis as a diagnostic target. As more companies invest in this area, the competitive landscape may shift, leading to more options for clinicians and patients. The success of this partnership could also encourage other diagnostic companies to seek similar collaborations with innovative biotech firms, fostering a more dynamic ecosystem for novel test development.
